Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Bansal, Nisha ^a   Hsu, Chi Yuan ^a   Chandra, Malini ^b   Iribarren, Carlos ^b   Fortmann, Stephen P ^c   Hlatky, Mark A ^c   Go, Alan S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DIVISION OF RESEARCH   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CREATININE BLOOD LEVEL; DATA BASE; DEATH; DISEASE ASSOCIATION; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; SELF REPORT; STROKE;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 80052834729     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-44     Document Type: Article

References (41)

1. Clinical Epidemiology of Cardiovascular Disease in Chronic Renal Disease. Foley RN, P P, Sarnak MJ, Am J of Kid Dis 1998 32 112 119 10.1053/ajkd.1998. v32.pm9820470
2. Poor Long Term Survival After Acute Myocardial Infarction Among Patients on Long Term Dialysis. Herzog CA, MJaCA, NEJM 1998 339 12 799 805 10.1056/NEJM199809173391203 9738087 (Pubitemid 28447453)
3. Level of Kidney Function as a Risk Factor for Cardiovascular Outcomes in the Elderly. Manjunath G, T H, Coresh J, et al. Kid International 2003 63 1121 1129 10.1046/j.1523-1755.2003.00838.x (Pubitemid 36315592)
4. Level of Kidney Function as a Risk Factor for Atherosclerotic Cardiovascular Outcomes in the Community. Manjunath G, T H, Ibrahim H, et al. J of Am Coll of Cardiol 2003 41 47 55 (Pubitemid 36044403)
5. Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. Weiner DE, T H, Amin MG, Stark PC, et al. J Am Soc Nephrol 2004 15 1307 1315 10.1097/01.ASN.0000123691.46138.E2 15100371 (Pubitemid 38526012)
6. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Reddan DN, Szczech L, Bhapkar MV, Moliterno DJ, Califf RM, Ohman EM, Berger PB, Hochman JS, Van De Werf F, Harrington RA, et al. Nephrol Dial Transplant 2005 20 10 2105 2112 10.1093/ndt/gfh981 16030030 (Pubitemid 41510084)
7. Patterns of Medication Use in the RRI-CKD Study: Focus on Medications with Cardiovascular Effects. Bailie GR, E G, Liu L, Roys R, Kiser M, et al. Nephrol Dial Transplant 2005 20 1110 1115 10.1093/ndt/gfh771 15769809 (Pubitemid 40862099)
8. Blood Pressure and Angiotensin Converting Enzyme Inhibitor Use in Hypertensive Patients with Chronic Renal Insufficiency. Hsu CY, B D, Kuperman BJ, Curhan GC, Am J Hypertens 2001 14 1219 1225 10.1016/S0895-7061(01)02202-6 11775130 (Pubitemid 33151478)
9. Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd BA, Nephrol Dial Transplant 2002 17 8 1426 1433 10.1093/ndt/17.8.1426 12147790
10. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD, Circulation 2010 121 3 357 365 10.1161/ CIRCULATIONAHA.109.865352 20065168
11. Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes. Patel UD, Ou FS, Ohman EM, Gibler WB, Pollack CV, Peterson ED, Roe MT, Am J Kidney Dis 2009 53 3 426 437 10.1053/j.ajkd.2008.09.024 19100672
12. Aspirin, Beta-Blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Berger AK, D S, Krumholz HM, J Am Coll Cardiol 2003 42 2 209 210 10.1016/S0735-1097(03)00590-4 12875752 (Pubitemid 36851406)
13. Renal Function, concomitant medication use and outcomes following acute coronary syndromes. Reddan DN, S L, Bhapkar MV, Moliterno DJ, et al. Nephrol Dial Transplant 2005 20 2105 2112 10.1093/ndt/gfh981 16030030 (Pubitemid 41510084)
14. Associations of kidney function with cardiovascular medication use after myocardial infarction. Winkelmayer WC, Levin R, Setoguchi S, Clin J Am Soc Nephrol 2008 3 5 1415 1422 10.2215/CJN.02010408 18614775
15. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, Moliterno DJ, Nassif D, Lopez JJ, Saucedo JF, JACC Cardiovasc Interv 2009 2 1 37 45 10.1016/j.jcin.2008.06.012 19463396
16. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M, McCullough PA, Am J Kidney Dis 2001 37 6 1191 1200 10.1053/ajkd.2001. 24522 11382688 (Pubitemid 32525155)
17. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ, Am Heart J 2002 144 2 226 232 10.1067/mhj.2002. 125513 12177638 (Pubitemid 34879643)
18. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, N Engl J Med 2004 351 13 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
19. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ, J Am Soc Nephrol 2005 16 2 489 495 10.1681/ASN.2004030203 15590763 (Pubitemid 41725146)
20. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. Herzog CA, Ma JZ, Collins AJ, N Engl J Med 1998 339 12 799 805 10.1056/NEJM199809173391203 9738087 (Pubitemid 28447453)
21. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? McCullough PA, J Am Coll Cardiol 2003 41 5 725 728 10.1016/S0735-1097(02)02955-8 12628713 (Pubitemid 36308376)
22. The California Automated Mortality Linkage System (CAMLIS). Arellano MG, Petersen GR, Petitti DB, Smith RE, Am J Public Health 1984 74 12 1324 1330 10.2105/AJPH.74.12.1324 6507683 (Pubitemid 15190025)
23. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA, Ann Intern Med 2006 144 4 229 238 16490908 (Pubitemid 46768205)
24. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Ann Intern Med 2006 145 4 247 254 16908915 (Pubitemid 46768608)
25. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Levey AS, B J, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 461 470 10075613 (Pubitemid 29135798)
26. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU, Kidney Int 2011 80 1 17 28 10.1038/ki.2010.483 21150873
27. A checklist for medication compliance and persistence studies using retrospective databases. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M, Value Health 2007 10 1 3 12 10.1111/j.1524-4733. 2006.00139.x 17261111 (Pubitemid 46161090)
28. Estimating medication persistency using administrative claims data. Sikka R, Xia F, Aubert RE, Am J Manag Care 2005 11 7 449 457 16044982 (Pubitemid 41022729)
29. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Hess LM, Raebel MA, Conner DA, Malone DC, Ann Pharmacother 2006 40 7-8 1280 1288 16868217 (Pubitemid 44204957)
30. Statin and B-Blocker Therapy and the Initial Presenation of Coronary Artery Disease. Go ASIC, Chandra M, et al. Annals of Internal Medicine 2006 144 4 229 238 16490908 (Pubitemid 46768205)
31. Evaluating hypertension control in a managed care setting. Alexander M, Tekawa I, Hunkeler E, Fireman B, Rowell R, Selby JV, Massie BM, Cooper W, Arch Intern Med 1999 159 22 2673 2677 10.1001/archinte.159.22.2673 10597757
32. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Sharp Collaborative G, Am Heart J 2010 160 5 785 794 e710 10.1016/j.ahj.2010.08.012 21095263
33. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK, J Am Coll Cardiol 2008 51 15 1448 1454 10.1016/j.jacc.2007.11.072 18402899 (Pubitemid 351471787)
34. Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes. Harada RK, Eagle KA, Kline-Rogers EM, Fang J, Smith D, Mukherjee D, Indian Heart J 2006 58 3 222 229 19033620
35. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M, Am J Kidney Dis 2010 55 1 42 49 10.1053/j.ajkd.2009.09.020 19932541
36. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, Am J Kidney Dis 2009 53 5 741 750 10.1053/j.ajkd.2008.11.025 19216014
37. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S, Ann Intern Med 2001 134 8 629 636 11304102 (Pubitemid 32322240)
38. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD, Circulation 2004 110 24 3667 3673 10.1161/01.CIR.0000149806.01354. BF 15569840 (Pubitemid 39665255)
39. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML, J Am Coll Cardiol 2004 44 8 1587 1592 10.1016/j.jacc.2004.06.072 15489090 (Pubitemid 39369790)
40. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Foley RN, Herzog CA, Collins AJ, Kidney Int 2002 62 5 1784 1790 10.1046/j.1523-1755.2002.00636.x 12371980 (Pubitemid 35286287)
41. Beta-blockers for coronary heart disease in chronic kidney disease. Chonchol M, Benderly M, Goldbourt U, Nephrol Dial Transplant 2008 23 7 2274 2279 10.1093/ndt/gfm950 18187497 (Pubitemid 351957591)